Q-omics provides the consensus-scored CYCSP52 profile across patient tissues and cancer cell-line models. CYCSP52 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CYCSP52 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, CYCSP52 RNA expression shows 15,940 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRP, THCA, and DLBC as cancer lineages where CYCSP52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP52 survival associations across molecular data types. CYCSP52 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP52 RNA expression–survival associations across cancer types. High CYCSP52 expression shows unfavorable associations in KIRP, LGG, UVM and READ, but favorable associations in STAD and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CYCSP52 RNA expression.
This table summarizes CYCSP52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP52 shows lower tumor expression in THCA and LUAD and higher tumor expression in KIRC, CHOL, STAD and ESCA. The THCA box plot shows higher CYCSP52 RNA expression in normal versus tumor tissue (log2 FC = −0.296, t-test p < 0.001).
This table shows molecular features associated with CYCSP52 in patient tissues and cancer cell lines. In patient samples, CYCSP52 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
